The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Exosomal microRNA signatures in multiple sclerosis reflect disease status
Abstract
Multiple Sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system (CNS). There is currently no single definitive test for MS. Circulating exosomes represent promising candidate biomarkers for a host of human diseases. Exosomes contain RNA, DNA, and proteins, can cross the blood-brain barrier, and are secreted from almost all cell types including cells of the CNS. We hypothesized that serum exosomal miRNAs could present a useful blood-based assay for MS disease detection and monitoring. Exosome-associated microRNAs in serum samples from MS patients ( n = 25) and matched healthy controls ( n = 11) were profiled using small RNA next generation sequencing. We identified differentially expressed exosomal miRNAs in both relapsing-remitting MS (RRMS) (miR-15b-5p, miR-451a, miR-30b-5p, miR-342-3p) and progressive MS patient sera (miR-127-3p, miR-370-3p, miR-409-3p, miR-432-5p) in relation to controls. Critically, we identified a group of nine miRNAs (miR-15b-5p, miR-23a-3p, miR-223-3p, miR-374a-5p, miR-30b-5p, miR-433-3p, miR-485-3p, miR-342-3p, miR-432-5p) that distinguished relapsing-remitting from progressive disease. Eight out of nine miRNAs were validated in an independent group ( n = 11) of progressive MS cases. This is the first demonstration that microRNAs associated with circulating exosomes are informative biomarkers not only for the diagnosis of MS, but in predicting disease subtype with a high degree of accuracy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Deleting miR-223 (miR-223-/-) could significantly delay EAE onset, alleviate spinal injury and decrease neurological symptoms in mice, demonstrating that miR-223 is a potential marker and therapeutic target for EAE (Figure 10) 123, 124.”
From miR-223: An Effective Regulator of Immune Cell Differentiation and Inflammation (2021) · cites this paper as [123]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Elements of Statistical Learning
Hastie, T., Tibshirani, R., & Friedman, J. (2009) · Springer Series in Statistics · doi:10.1007/978-0-387-84858-7 · Cited by 25,970
The Molecular Signatures Database Hallmark Gene Set Collection
Liberzon, A., Birger, C., Thorvaldsdóttir, H., Ghandi, M., Mesirov, J. P., & Tamayo, P. (2015) · Cell Systems · doi:10.1016/j.cels.2015.12.004 · Cited by 13,807
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria
Polman, C. H., Reingold, S. C., Banwell, B., Clanet, M., Cohen, J. A., Filippi, M., Fujihara, K., Havrdova, E., Hutchinson, M., Kappos, L., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22366 · Cited by 9,802
Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes
Alvarez-Erviti, L., Seow, Y., Yin, H., Betts, C., Lakhal, S., & Wood, M. J. A. (2011) · Nature Biotechnology · doi:10.1038/nbt.1807 · Cited by 4,930
Defining the clinical course of multiple sclerosis: The 2013 revisions
Lublin, F. D., Reingold, S. C., Cohen, J. A., Cutter, G. R., Sørensen, P. S., Thompson, A. J., Wolinsky, J. S., Balcer, L. J., Banwell, B., Barkhof, F., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000560 · Cited by 3,177
Plasma processing conditions substantially influence circulating microRNA biomarker levels
Cheng, H. H., Yi, H. S., Kim, Y., Kroh, E. M., Chien, J. W., Eaton, K. D., Goodman, M. T., Tait, J. F., Tewari, M., & Pritchard, C. C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064795 · Cited by 317
Research works printed but not linked: 39
- Nicholas, R. R. W. Multiple sclerosis. Multiple Sclerosis. Am Fam Physician 87, 712–714 (2013).
- Katz Sand, I. Classification, diagnosis, and differential diagnosis of multiple sclerosis. Curr Opin Neurol 28, 193–205 (2015). · DOI
- Housley, W. J., Pitt, D. & Hafler, D. A. Biomarkers in multiple sclerosis. Clin Immunol 161, 51–8 (2015). · DOI
- Zhou, X. & Yang, P. C. MicroRNA: a small molecule with a big biological impact. MicroRNA 1 (2012). · DOI
- Cheng, L., Sharples, R.A., Scicluna, B.J. & Hill, A.F. Exosomes provide a protective and enriched source of miRNA for biomarker profiling compared to intracellular and cell-free blood. J Extracell Vesicles 3 (2014). · DOI · Paper page
- Lee, J. Y., Park, J. K., Lee, E. Y., Lee, E. B. & Song, Y. W. Circulating exosomes from patients with systemic lupus erythematosus induce an proinflammatory immune response. Arthritis Res Ther 18, 264 (2016). · DOI
- Momen-Heravi, F. et al. Increased number of circulating exosomes and their microRNA cargos are potential novel biomarkers in alcoholic hepatitis. J Transl Med 13, 261 (2015). · DOI
- Pusic, A. D., Pusic, K. M. & Kraig, R. P. What are exosomes and how can they be used in multiple sclerosis therapy? Expert Rev Neurother 14, 353–5 (2014). · DOI
- McKay, K. A., Kwan, V., Duggan, T. & Tremlett, H. Risk factors associated with the onset of relapsing-remitting and primary progressive multiple sclerosis: a systematic review. Biomed Res Int 2015, 817238 (2015). · DOI
- Xiao, F. et al. miRecords: an integrated resource for microRNA-target interactions. Nucleic Acids Res 37, D105–10 (2009). · DOI
- Chou, C. H. et al. miRTarBase 2016: updates to the experimentally validated miRNA-target interactions database. Nucleic Acids Res 44, D239–47 (2016). · DOI
- Sethupathy, P., Corda, B. & Hatzigeorgiou, A. G. TarBase: A comprehensive database of experimentally supported animal microRNA targets. RNA 12, 192–7 (2006). · DOI
- Ru, Y. et al. The multiMiR R package and database: integration of microRNA-target interactions along with their disease and drug associations. Nucleic Acids Res 42, e133 (2014). · DOI
- Lobb, R. J. et al. Optimized exosome isolation protocol for cell culture supernatant and human plasma. J Extracell Vesicles 4, 27031 (2015). · DOI
- Fenoglio, C. et al. Effect of fingolimod treatment on circulating miR-15b, miR23a and miR-223 levels in patients with multiple sclerosis. J Neuroimmunol 299, 81–83 (2016). · DOI
- Fenoglio, C. et al. Decreased circulating miRNA levels in patients with primary progressive multiple sclerosis. Multiple Sclerosis Journal 19, 1938–1942 (2013). · DOI
- Gandhi, R. miRNA in multiple sclerosis: search for novel biomarkers. Mult Scler 21, 1095–103 (2015). · DOI
- Gandhi, R. et al. Circulating MicroRNAs as biomarkers for disease staging in multiple sclerosis. Annals of Neurology 73, 729–740 (2013). · DOI
- Guerau-de-Arellano, M., Alder, H., Ozer, H. G., Lovett-Racke, A. & Racke, M. K. miRNA profiling for biomarker discovery in multiple sclerosis: from microarray to deep sequencing. J Neuroimmunol 248, 32–9 (2012). · DOI
- Junker, A. et al. MicroRNA profiling of multiple sclerosis lesions identifies modulators of the regulatory protein CD47. Brain 132, 3342–52 (2009). · DOI · Paper page
- Keller, A. et al. Comprehensive analysis of microRNA profiles in multiple sclerosis including next-generation sequencing. Mult Scler 20, 295–303 (2014). · DOI
- Keren Regev, A. P. et al. Comprehensive evaluation of serum microRNAs as biomarkers in multiple sclerosis. Neuroimmunology & Neuroinflammation (2016). · DOI
- Lin, S. T. & Fu, Y. H. miR-23 regulation of lamin B1 is crucial for oligodendrocyte development and myelination. Dis Model Mech 2, 178–88 (2009). · DOI
- Fenoglio, C., Ridolfi, E., Galimberti, D. & Scarpini, E. MicroRNAs as active players in the pathogenesis of multiple sclerosis. Int J Mol Sci 13, 13227–39 (2012). · DOI
- Sarchielli, P. et al. Fibroblast growth factor-2 levels are elevated in the cerebrospinal fluid of multiple sclerosis patients. Neurosci Lett 435, 223–8 (2008). · DOI
- Aziz, F. The emerging role of miR-223 as novel potential diagnostic and therapeutic target for inflammatory disorders. Cell Immunol 303, 1–6 (2016). · DOI
- Iglesias, A. H. et al. Microarray detection of E2F pathway activation and other targets in multiple sclerosis peripheral blood mononuclear cells. J Neuroimmunol 150, 163–77 (2004). · DOI
- Igci, M. et al. Gene expression profiles of autophagy-related genes in multiple sclerosis. Gene 588, 38–46 (2016). · DOI
- Maciotta, S., Meregalli, M. & Torrente, Y. The involvement of microRNAs in neurodegenerative diseases. Front Cell Neurosci 7, 265 (2013). · DOI
- Boese, A. S. et al. MicroRNA abundance is altered in synaptoneurosomes during prion disease. Mol Cell Neurosci 71, 13–24 (2016). · DOI
- Lugli, G. et al. Plasma Exosomal miRNAs in Persons with and without Alzheimer Disease: Altered Expression and Prospects for Biomarkers. PLoS One 10, e0139233 (2015). · DOI · Paper page
- Alice Serafin, L. F. et al. and Christine Schwienbacher. Identification of a set of endogenous reference genes for miRNA expression studies in Parkinson’s disease blood samples. BMC research notes 7, 715 (2014). · DOI
- Kalinowska-Lyszczarz, A. & Losy, J. The role of neurotrophins in multiple sclerosis-pathological and clinical implications. Int J Mol Sci 13, 13713–25 (2012). · DOI
- Elovaara, I. U. M. et al. Adhesion molecules in multiple sclerosis: relation to subtypes of disease and methylprednisolone therapy. Arch Neurol. 57, 546–51 (2000). · DOI
- Fletcher, J. M., Lalor, S. J., Sweeney, C. M., Tubridy, N. & Mills, K. H. T cells in multiple sclerosis and experimental autoimmune encephalomyelitis. Clin Exp Immunol 162, 1–11 (2010). · DOI
- McDonald, J. S., Milosevic, D., Reddi, H. V., Grebe, S. K. & Algeciras-Schimnich, A. Analysis of circulating microRNA: preanalytical and analytical challenges. Clin Chem 57, 833–40 (2011). · DOI
- Lotvall, J. et al. Minimal experimental requirements for definition of extracellular vesicles and their functions: a position statement from the International Society for Extracellular Vesicles. J Extracell Vesicles 3, 26913 (2014). · DOI · Paper page
- Li, C. C. et al. Glioma microvesicles carry selectively packaged coding and non-coding RNAs which alter gene expression in recipient cells. RNA Biol 10, 1333–44 (2013). · DOI
- Seni, G. & Elder, J. F. Ensemble Methods in Data Mining: Improving Accuracy Through Combining Predictions. Synthesis Lectures on Data Mining and Knowledge Discovery 2, 1–126 (2010). · DOI
Cited by
The role of glial cells in multiple sclerosis disease progression
Healy, L. M., Stratton, J. A., Kuhlmann, T., & Antel, J. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-022-00624-x · Cited by 152
miR-223: An Effective Regulator of Immune Cell Differentiation and Inflammation
Jiao, P., Wang, X.-P., Luoreng, Z.-M., Yang, J., Jia, L., Ma, Y., & Wei, D.-W. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.59876 · Cited by 151
Liguori, M., Nuzziello, N., Introna, A., Consiglio, A., Licciulli, F., D’Errico, E., Scarafino, A., Distaso, E., & Simone, I. L. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00288 · Cited by 131
Different sourced extracellular vesicles and their potential applications in clinical treatments
Bahmani, L., & Ullah, M. (2022) · Cells · doi:10.3390/cells11131989 · Cited by 83
Xu, X., Iqbal, Z., Xu, L., Wen, C., Duan, L., Xia, J., Yang, N., Zhang, Y., & Liang, Y. (2024) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13610 · Cited by 68
Metadata
- Authors
- Ebrahimkhani, S., Vafaee, F., Young, P. E., Hur, S. S. J., Hawke, S., Devenney, E., Beadnall, H., Barnett, M. H., Suter, C. M., & Buckland, M. E.
- Venue
- Scientific Reports
- Published
- 2017-10-30
- Volume
- 7
- Issue
- 1
- ISSN
- 2045-2322
- Cited by
- 247
- References
- 6
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Exosomal microRNA signatures in multiple sclerosis reflect disease status. https://app.cochat.ai/papers/10.1038/s41598-017-14301-3
- The paper
- Ebrahimkhani, S., Vafaee, F., Young, P. E., Hur, S. S. J., Hawke, S., Devenney, E., Beadnall, H., Barnett, M. H., Suter, C. M., & Buckland, M. E. (2017). Exosomal microRNA signatures in multiple sclerosis reflect disease status. Scientific Reports. https://doi.org/10.1038/s41598-017-14301-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.